Sosei Group Co. (OTCMKTS:SOLTF – Get Free Report) shares crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $16.24 and traded as low as $10.65. Sosei Group shares last traded at $10.65, with a volume of 300 shares.
Wall Street Analysts Forecast Growth
A number of equities research analysts have weighed in on the company. Jefferies Financial Group downgraded Sosei Group from a “buy” rating to an “underperform” rating in a research report on Tuesday, June 27th. Citigroup downgraded Sosei Group from a “buy” rating to a “sell” rating in a research report on Wednesday, June 28th.
Get Our Latest Stock Report on SOLTF
Sosei Group Price Performance
Sosei Group Company Profile
Sosei Group Corporation develops biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair to treat asthma; and ORAVI, an oropharyngeal candidiasis. The company's product pipeline consists of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; HTL0016878 for Schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; and PF-07258669 for anorexia.
See Also
- Five stocks we like better than Sosei Group
- Compound Interest and Why It Matters When Investing
- WeWork Stock Soars: Meme Stock Madness or Mirage?
- How to Use the MarketBeat Stock Split Calculator
- Shutterstock is the Value Stock they don’t want you to know about
- How to Most Effectively Use the MarketBeat Earnings Screener
- 3 Low-Cost ETFs That Are Crushing SPY
Receive News & Ratings for Sosei Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sosei Group and related companies with MarketBeat.com's FREE daily email newsletter.